# Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)

> **NCT02856867** · PHASE2 · WITHDRAWN · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC**

## Conditions studied

- Esophagogastric Adenocarcinoma
- Metastatic Disease
- No Previous Chemotherapy for Metastatic Esophagogastric Cancer

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Oxaliplatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02856867
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-12
- **Primary completion:** 2019-06
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02856867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02856867, "Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02856867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*